Clinical trial · Interventional
Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
NCT06694636CI-TRIAL-00082727recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients who met the inclusion criteria were treated with endovascular radiofrequency ablation and desympathetic nerve surgery. After enrollment, endovascular radiofrequency ablation and desympathetic surgery were performed. After radiofrequency ablation, the safety and efficacy of follow-up treatment will be carried out every 1 month or so, including blood routine, liver and kidney function, tumor indicators, abdominal CT/magnetic resonance, etc.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| endovascular radiofrequency ablation and desympathetic nerve surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intravascular Radiofrequency Ablation of Sympathetic Nerves Group
- description
- Enrolled patients will receive Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
- interventionNames
- Procedure: endovascular radiofrequency ablation and desympathetic nerve surgery
Primary outcomes (1)
- measure
- ORR
- timeFrame
- every month, up to 1 year
- description
- Objective Response Rate
Secondary outcomes (2)
- measure
- PFS
- timeFrame
- every month, up to 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 25 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Clinically or pathologically confirmed hepatocellular carcinoma (HCC) * Locally progressed or distant metastatic unresectable advanced HCC * Progressed after second-line therapy * Agree to participate in the study and sign the informed consent form Exclusion Criteria: * Not suitable for ablation surgery * Pregnant, lactating and planning to become pregnant * Orthostatic hypotension * Mixed liver cancer * Intestinal obstruction * Obvious bleeding tendencies and hematologic diseases * Acute or severe systemic infection; * Stroke or transient ischemic attack (TIA) within two weeks; * Acute coronary syndrome within two weeks; * Evaluated to be not suitable for this trial by investigators
References
Publications (0)
Data not yet available
No reference posted for this study.